Myrbetriq Free Sample Program Overview And Eligibility Criteria

Oct. 8, 2025, 9:25 p.m.

Tags: myrbetriq

Introduction

For patients seeking treatment for overactive bladder (OAB), Myrbetriq (mirabegron extended-release tablets) is a prescription medication designed to manage symptoms such as urgency, frequency, and urinary leakage. Given the cost of prescription medications, some patients may explore options for obtaining free samples or assistance through patient support programs. Myrbetriq offers a free sample program through Astellas Pharma Support Solutions, allowing eligible patients to access the medication at no cost. This article provides a detailed overview of the Myrbetriq free sample program, including eligibility requirements, how to apply, and important safety information. The information is drawn from official sources, including the Astellas Pharma website, the Myrbetriq patient support portal, and the medication’s prescribing information.

Overview of the Myrbetriq Free Sample Program

The Myrbetriq free sample program is administered by Astellas Pharma Support Solutions and is available to patients who meet specific eligibility criteria. This program allows qualified individuals to receive the medication at no cost, provided they fulfill all requirements outlined in the program guidelines.

According to the Astellas Pharma Support Solutions website, patients must be prescribed Myrbetriq by a healthcare provider and must demonstrate that they meet the program’s financial and medical eligibility standards. The program is intended to assist patients who may not have insurance coverage for the medication or who face financial barriers to accessing it through standard prescription channels.

Eligibility for the free sample program is determined by a trained program representative, who evaluates the patient’s application and confirms that they meet the necessary conditions. Once approved, patients can receive Myrbetriq free of charge, either through in-office dispensing by a healthcare provider or via direct shipment to their home.

Eligibility Requirements for the Myrbetriq Free Sample Program

To qualify for the Myrbetriq free sample program, patients must meet all of the following criteria:

Must be a U.S. resident
The program is available only to patients living within the United States.
Must have a valid prescription for Myrbetriq
A healthcare provider must have prescribed Myrbetriq for the treatment of overactive bladder.
Must meet financial eligibility guidelines
Patients must demonstrate that they cannot afford the medication through standard prescription channels. The specific income thresholds and documentation requirements are outlined in the program’s terms of service.
Must not have insurance coverage for Myrbetriq
Patients who are covered by an insurance plan that does not cover Myrbetriq or provides inadequate coverage may be eligible.
Must not be enrolled in other prescription assistance programs
Patients who are currently receiving the medication through another assistance program may not be eligible for the Myrbetriq free sample program.
Must not have severe uncontrolled hypertension
Myrbetriq may increase blood pressure in some patients. The medication is not recommended for individuals with severe uncontrolled hypertension (defined as systolic blood pressure ≥ 180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg).
Must not have a known hypersensitivity to mirabegron or its inactive ingredients
The medication is contraindicated in patients with known allergies to mirabegron or any of the inactive components of the tablet.

How to Apply for the Myrbetriq Free Sample Program

Patients who believe they meet the eligibility requirements can apply for the Myrbetriq free sample program through the Astellas Pharma Support Solutions website or by contacting a trained program representative. The application process typically involves the following steps:

Review eligibility criteria
Patients should carefully review the eligibility requirements to determine if they qualify for the program.
Submit an application
An application can be submitted online through the Astellas Pharma Support Solutions portal. Patients will be required to provide personal and medical information, including their prescription details and proof of income.
Wait for approval
A program representative will review the application and determine whether the patient is eligible. If approved, the patient will receive instructions on how to obtain the medication.
Receive the medication
Once approved, patients can receive Myrbetriq through in-office dispensing by their healthcare provider or via direct shipment to their home address.

Important Safety Information for Myrbetriq

Before starting the Myrbetriq free sample program, patients should be aware of the important safety information associated with the medication. Myrbetriq is a prescription drug and must be used under the supervision of a qualified healthcare provider.

Contraindications

Myrbetriq is contraindicated in patients with known hypersensitivity to mirabegron or any of the inactive ingredients in the tablet. It is also not recommended for patients with severe uncontrolled hypertension.

Potential Side Effects

The most commonly reported adverse reactions in clinical trials include:
- Dry mouth
- Urinary tract infection
- Constipation
- Tachycardia

In postmarketing experience, additional side effects have been reported, including:
- Atrial fibrillation
- Nausea
- Diarrhea
- Dizziness

Patients should monitor their symptoms and report any unusual side effects to their healthcare provider immediately.

Drug Interactions

Myrbetriq may interact with other medications, including:
- Thioridazine (Mellaril™ and Mellaril-S™)
- Flecainide (Tambocor®)
- Propafenone (Rythmol®)
- Digoxin (Lanoxin®)
- Solifenacin succinate (VESIcare®)

Patients should inform their doctor about all medications they are currently taking, including over-the-counter drugs and herbal supplements.

Precautions

Before taking Myrbetriq, patients should inform their doctor about any existing medical conditions, particularly:
- Liver or kidney problems
- Bladder outlet obstruction (BOO)
- History of high blood pressure

Myrbetriq may increase blood pressure in some patients, so regular monitoring is recommended, especially for individuals with pre-existing hypertension.

Monitoring and Follow-Up

Patients who receive Myrbetriq through the free sample program should maintain regular follow-up appointments with their healthcare provider. These visits allow the doctor to assess the effectiveness of the medication and monitor for any potential side effects.

Myrbetriq and Combination Therapy with Solifenacin Succinate

In some cases, Myrbetriq may be prescribed in combination with solifenacin succinate, another medication used to treat overactive bladder. When used together, these medications may offer improved symptom control for patients. However, the combination also increases the risk of certain side effects, particularly those related to the urinary system and cardiovascular function.

Patients taking Myrbetriq in combination with solifenacin succinate should be closely monitored for signs of urinary retention, which has been reported in patients with bladder outlet obstruction (BOO) or those taking muscarinic antagonist medications. While clinical studies have not shown an increased risk of urinary retention in patients treated with mirabegron alone, caution is still advised when combining Myrbetriq with other medications that affect bladder function.

Patients should also be aware that the combination of Myrbetriq and solifenacin succinate may increase the risk of adverse reactions such as dry mouth, urinary tract infections, and constipation. These side effects are generally more pronounced when both medications are used together compared to when either is used alone.

Reporting Side Effects and Adverse Events

Patients who experience any side effects or adverse events while taking Myrbetriq should report them to their healthcare provider as soon as possible. In addition, patients are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA).

The FDA provides several options for reporting adverse events:
- Visit the FDA MedWatch website at www.fda.gov/medwatch.
- Call the FDA MedWatch toll-free number at 1-800-FDA-1088.

Reporting side effects helps the FDA monitor the safety of prescription medications and identify any potential risks that may not have been previously recognized.

Conclusion

The Myrbetriq free sample program offers eligible patients the opportunity to access a prescription medication for overactive bladder at no cost. Administered by Astellas Pharma Support Solutions, the program requires patients to meet specific eligibility criteria, including financial and medical requirements. Patients must have a valid prescription for Myrbetriq and demonstrate that they cannot afford the medication through standard prescription channels.

Before starting the program, patients should be aware of the important safety information associated with Myrbetriq, including potential side effects, drug interactions, and contraindications. Regular monitoring and follow-up with a healthcare provider are essential to ensure the medication is both effective and safe.

For patients considering the Myrbetriq free sample program, it is important to review all program guidelines and consult with a qualified healthcare provider before beginning treatment. The Astellas Pharma Support Solutions website provides additional information for patients interested in applying for the program.